|
RSBN1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
3.21280002602009E-09 |
| Normal-vs-Stage3 |
9.88098491916389E-15 |
| Normal-vs-Stage4 |
5.00710584105946E-14 |
| Stage1-vs-Stage2 |
5.506600E-01 |
| Stage1-vs-Stage3 |
3.210400E-02 |
| Stage1-vs-Stage4 |
7.215500E-03 |
| Stage2-vs-Stage3 |
3.852600E-01 |
| Stage2-vs-Stage4 |
9.991600E-02 |
| Stage3-vs-Stage4 |
3.358600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.25195426142955E-12 |
| Normal-vs-AfricanAmerican |
2.422500E-04 |
| Normal-vs-Asian |
3.69659858279192E-11 |
| Caucasian-vs-AfricanAmerican |
8.847900E-02 |
| Caucasian-vs-Asian |
6.239200E-01 |
| AfricanAmerican-vs-Asian |
8.253900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-16 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
4.201400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.91324733833653E-12 |
| Normal-vs-Age(41-60Yrs) |
1.33226762955019E-15 |
| Normal-vs-Age(61-80Yrs) |
3.91242593877905E-13 |
| Normal-vs-Age(81-100Yrs) |
4.41500000000206E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.121200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.972000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.554960E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.410800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.244600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.598200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.783380E-04 |
| Classical-VS-Follicular |
5.371800E-01 |
| Classical-VS-Other |
5.674200E-01 |
| Classical-VS-Normal |
9.21449583302092E-11 |
| Tall-VS-Follicular |
4.588200E-04 |
| Tall-VS-Other |
2.302800E-01 |
| Tall-VS-Normal |
1.65423230669148E-14 |
| Follicular-VS-Other |
4.974000E-01 |
| Follicular-VS-Normal |
1.59970003910104E-09 |
| Other-VS-Normal |
1.118760E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22044604925031E-16 |
| Normal-vs-N1 |
1.48400181032571E-11 |
| N0-vs-N1 |
3.264800E-01 |
|
|
